Brief: Puma Biotechnology Presents Outcomes From The Metastatic Breast Cancer Cohort
06/06/2022 14:11
June 6 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY PRESENTS OUTCOMES FROM THE METASTATIC
BREAST
CANCER COHORT OF THE SUMMIT TRIAL AT THE ASCO 2022 ANNUAL
MEETING
Source text for Eikon: ID:nBw6x45pTa
Further company coverage: PBYI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2